Strategies for Accelerating the Development of Modified Release Oral Forms
6 / 65 articles displayed
News
Quotient Sciences, today announced plans to present on the latest Tufts CSDD White Paper assessing the timeline reductions and multi-million dollar cost savings of Translational Pharmaceutics® at Biotech Showcase 2020™, to be held January 13-15, during the most important week in healthcare at the Hilton San Francisco Union Square.
Awards
Quotient Sciences has won the Deal of the Year award at the 2019 Medilink East Midlands Business Awards. The Deal of the Year award recognises entrepreneurship of an individual or team in executing a truly transformational and high-value deal for both the company and the East Midlands Life Sciences sector
News
Tufts Center for the Study of Drug Development (CSDD) today published a white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms.
News
Quotient Sciences, the innovative drug development and manufacturing organization, today announces the appointment of Claes Glassell as non‐executive chairman of its board of directors. A highly accomplished leader in the pharmaceutical industry with over 35 years’ experience, Glassell has held numerous leadership positions, including at the board level, to help companies through high phases of growth.
News
Quotient Sciences to Recapitalize With Global Private Equity Firm Permira
News
Quotient’s Andy Lewis appointed as Secretary of Controlled Release Society
Ask us a question
